We are testing a new oral medication for patients with AML or other blood cancers that have an IDH1 mutation. The study aims to evaluate the safety and activity of this investigational drug.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Myeloid Leukaemia (AML) is a fast-growing cancer of the blood and bone marrow that results in the overproduction of immature white blood cells, leading to symptoms such as fatigue, frequent infections, and easy bruising or bleeding.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.